Milton (Milt) B. McColl
BS ’81, MD ’88 (1ST TERM, 2010-2013) (2ND TERM 2013-2016)
Milt joined the Board of Gauss in the summer of 2011 and became CEO in October of 2011. Prior to that he had been working closely with the company’s founders during the spring of 2011 while he was mentoring students during the 2011 Stanford Biodesign course. As CEO, Milt has raised over $6M for Gauss as they have completed developed of and received FDA clearance for the Gauss iPad Mobile App. Previous to Gauss, in April 2007, Milt was hired as a Venture Partner with New Leaf Venture Partners (NLVP). NLVP managed over a billion dollars in Life Science investments and Milt’s focus was investing in medical device companies. While at NLVP, Milt lead investments and served on the board of Illuminoss and Glumetrics. For four years he also served on the board of Interlace which was sold to Hologics in January 2011. Milt left NLVP in June of 2011.
Prior to joining New Leaf, Milt was President of the Neurovascular Division of Boston Scientific Corporation (BSC). Milt initially joined BSC in 2001 following the acquisition of Embolic Protection, Inc (EPI) where he served as Vice President and General Manager for the Embolic Protection Franchise, part of the Interventional Cardiology division of BSC. Milt joined EPI in 2000 as one of their first employees as the Vice President of Clinical, Regulatory and Quality Affairs and Chief Medical Officer. Previously, Milt was CEOof Genitope, Inc., CEO of CSFluids, Inc. (later renamed Eunio), Vice President of Regulatory Affairs, Quality Affairs, Clinical Affairs and Chief Medical Officer for Gynecare, Inc. (eventually acquired by Johnson and Johnson) and Director of Marketing for Origin Medsystems (acquired by Eli Lilly/Guidant Corporation).
Milt began his career as a professional football player with the San Francisco Forty-Niners and Los Angeles Raiders from 1981 to 1988. He was a member of two Super Bowl Championship teams for the Forty-Niners and was a special team’s captain.